Decision: Parallel import licences granted in 2026

As with any medicine, the MHRA will keep the safety and effectiveness of teplizumab under close review.

Pharmacy (P), prescription-only (POM), and general sale list (GSL) medicines: apply to move your medicine to a different classification.

These reports outline the MHRA’s Corporate and Business Plans, detailing the agency’s strategic direction over the next three years.

Guidance on using non-investigational medicinal products in a clinical trial.

Marketing authorisations Granted in 2026.

The pilot will help sponsors prepare for a new substantial modifications process under upcoming regulations, with responses delivered within 14 days.